MediWound vs Sol-Gel Technologies
MDWD and SLGL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MDWD and SLGL compare
Sol-Gel Technologies grew revenue faster over the last twelve months (68.0% versus −16.1% for MediWound).
Sol-Gel Technologies scores higher on the StockData Score (10 against 2 for MediWound), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MDWD | SLGL |
|---|---|---|
| Size and price | ||
| Share price | $12.97 | $55.12 |
| Change, 1 year | −30.0% | 75.0% |
| Change, 5 years | −35.4% | −35.7% |
| Beta (5Y) | 0.90 | 1.00 |
| Employees | 35 | 28 |
| StockData Score | ||
| Total score | 2 | 10 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 0 | 3 (better) |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −16.1% | 68.0% (better) |
| Revenue growth, 5Y average | −4.9% | 17.2% (better) |
| Profitability | ||
| Gross margin | 19.2% | – |
| Operating margin | −149% | −38.9% (better) |
| Net margin | – | −31.6% |
| FCF margin | −128% | 1.4% (better) |
| Return on equity | – | −15.3% |
| Return on invested capital | – | −153% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −10.3× | – |
| Current ratio | 2.32 | 10.37 (better) |
| Piotroski F-score | – | 5 |
| Ownership | ||
| Held by institutions | 45.3% | 47.5% |
| Held by insiders | 23.4% | 70.2% |
| Insider net buying, 12 months | $60.6K | $11.0M (better) |
| Short interest, % of float | 18.2% | 16.3% |
Go deeper
- MDWD stock overview
- MDWD income statement
- MDWD valuation and score
- SLGL stock overview
- SLGL income statement
- SLGL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.